No products in the cart.
Pre-made Durvalumab benchmark antibody ( Whole mAb, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-159
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Durvalumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1¦Ê) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
| Products Name (INN Index) | Pre-Made Durvalumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody |
|---|---|
| INN Name | Durvalumab |
| Target | CD274 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5xj4:HL/5x8m:BC |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Advaxis,AIO Studien gGmbH,AstraZeneca,Big Ten Cancer Research Consortium,Canadian Cancer Trials Group,Case Comprehensive Cancer Center,Celgene International SARL,Centre hospitalier de l'Universite de |
| Conditions Approved | Non-small cell lung cancer,Urogenital cancer,Small cell lung cancer |
| Conditions Active | Biliary cancer,Bladder cancer,Cervical cancer,Fallopian tube cancer,Head and neck cancer,Liver cancer,Ovarian cancer,Peritoneal cancer,Renal cell carcinoma,Solid tumours,Breast cancer,Gynaecological |
| Conditions Discontinued | CNS cancer,Lymphoproliferative disorders,Thyroid cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD274 |
| Package |
Previous slide
Next slide
